Compare Repligen Corporation Common Stock (RGEN) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Visa Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Visa Inc trades at $394.63 (market cap $743.55B). The key difference: Visa Inc is far larger — about 66.7× Repligen Corporation Common Stock's market cap, and Visa Inc pays a 0.68% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Visa Inc for 115 Days on average.
| RGEN | V | |
|---|---|---|
Market Cap | $11.14B | $743.55B |
Volume | 1,259,263 | 7,478,804 |
Sector | Health | Financials |
52-Week High | $194.57 | $396.06 |
52-Week Low | $102.87 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $11.02B | $754.13B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Visa (V) trades at $391.43, up 0.55% today, showing strong momentum near its resistance level of $392. The stock maintains bullish technical signals with consistent earnings beats in recent quarters and robust profitability metrics including 50.78% net margin and 61.79% ROE. Recent developments include the launch of Intelligent Commerce Connect for AI-powered commerce and expanded stablecoin partnerships, positioning Visa at the forefront of payment innovation.
Visa presents a compelling investment case with 85% analyst buy ratings and a $423.29 consensus price target representing 8% upside. Strong fundamentals are supported by $40B revenue and $20.1B net income for 2025, though elevated valuation ratios (P/E 33.71) and emerging fintech competition pose risks. The stock's outlook remains positive given its dominant market position and AI-driven growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
